Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer

NCT07365995 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT07365995
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07365995 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer
Lead sponsor
BioNTech SE
Phase
Phase 3
Overall status
Recruiting
Start date
April 22, 2026
Completion date
February 28, 2031
Enrollment
736 (estimated)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer